Business
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
First randomized, clinical study demonstrating prognostic value of Decipher Prostate test in postoperative salvage setting without hormone therapy SOUTH SAN
About this update from Veracyte, Inc.
[{"type":"text","content":"\nFirst randomized, clinical study demonstrating prognostic value of Decipher Prostate test in postoperative salvage setting without hormone therapy\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) today announced the publication of data reinforcing the clinical utility of the Decipher Prostate genomic classifier for helping to guide the timing and intensity of therapy in men experiencing prostate cancer recurrence following radical prostatectomy (RP). The findings, from an ancillary study of the prospective open-label, multicenter, randomized phase 3 SAKK 09/10 trial conducted at 28 centers in Belgium, Germany, and Switzerland, appear in Annals of Oncology.\n\nIt is estimated that more than 40 percent of men with intermediate- or high-risk prostate cancer may experience a biochemical disease recurrence after RP, which is characterized by rising levels of serum prostate-specific antigen (PSA). For men who experience a rising PSA, determining the optimal timing to initiate salvage radiotherapy (SRT) and whether to add androgen deprivation therapy (ADT) to SRT is challenging. This decision is important in part because the side effects of ADT when given concurrently with SRT are often difficult for patients to manage and are associated with long-term cardiovascular impact of hormone therapy.\n\n“Each year in the United States, tens of thousands of men are diagnosed with biochemically recurrent prostate cancer, yet conventional clinical measures such as PSA and Gleason score are often insufficient to predict which of them will do well with SRT alone and who will need more intensive therapy to improve their oncologic outcomes,” said Elai Davicioni, Ph.D., Veracyte’s medical director for urology. “The data from this study suggest that the Decipher Prostate genomic classifier can help fill this gap by providing objective information to guide customized treatment planning in the postoperative setting.”\n\nResearchers in the Swiss Group for Clinical Cancer Research (SAKK) and collaborating cancer centers assessed the clinical outcomes and Decipher Prostate genomic risk for 226 prostate cancer patients from the SAKK 09/10 trial, which randomized patients to standard vs. dose-escalated SRT. This study involved men experiencing a rise in PSA following RP, all of whom received SRT without the addition of ADT....